India Exchange Filings

Q2 FY27 Earnings and Board Meeting Highlights

Cohance Lifesciences Ltd reports Q2 FY27 revenue of ₹476.65 crore and net profit of ₹15.22 crore

  • Revenue rose 12.9% sequentially but fell 14.2% year-on-year; adjusted EBITDA margin improved to 10% from 2.2% in Q1 FY27.
  • Net profit compared with a ₹24.12 crore loss in Q1 FY27 and ₹74.08 crore profit in Q2 FY26; no exceptional item was reported, and limited-review conclusions were unmodified.
  • Board approved Dr. Kuber Jagdale’s appointment as CTO and Executive Director, subject to shareholder approval, and a proposed 26% investment in a captive solar-generation SPV.
  • Company disclosed a TGPCB closure order for its Suryapet facility following an industrial accident.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.